Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma

Cancer Letters

Volumn 319, Issue 1, 2012, Pages 66-82

  Schäfer, Heiner ^a   Dieckmann, Chantal ^a   Korniienko, Olena ^a   Moldenhauer, Gerhard ^b   Kiefel, Helena ^b   Salnikov, Alexey ^b   Krüger, Achim ^c   Altevogt, Peter ^b   Sebens, Susanne ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

CD171; Chemoresistance; L1CAM antibodies; Ovarian cancer; Pancreatic cancer

Indexed keywords

CD31 ANTIGEN; CELL ADHESION MOLECULE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L1-14.10; MONOCLONAL ANTIBODY L1-9.3/2A; PACLITAXEL; PROCASPASE 8; PROTEIN L1CAM; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INHIBITION; CELL INFILTRATION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CYTOSTATIC AGENTS; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, SCID; NEURAL CELL ADHESION MOLECULE L1; OVARIAN NEOPLASMS; PACLITAXEL; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

MUS;

EID: 84858069821     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.12.035     Document Type: Article

References (49)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics 2011. CA Cancer J. Clin. 2011, 61:212-236.
2. Schneider G., Siveke J.T., Eckel F., Schmid R.M. Pancreatic cancer: basic and clinical aspects. Gastroenterology 2005, 128:1606-1625.
3. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 2004, 351:2519-2529.
4. Müerköster S., Wegehenkel K., Arlt A., Witt M., Sipos B., Kruse M.-L., Sebens T., Klöppel G., Kalthoff H., Fölsch U.R., Schäfer H. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res. 2004, 64:1331-1337.
5. Arlt A., Vorndamm J., Müerköster S., Yu H., Schmidt W.E., Fölsch U.R., Schäfer H. Autocrine production of Interleukin-1-beta confers constitutive NFκB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res. 2002, 62:910-916.
6. Miyamoto H., Murakami T., Tsuchida K., Sugino H., Miyake H., Tashiro S. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 2004, 28:38-44.
7. Hagmann W., Jesnowski R., Faissner R., Guo C., Löhr J.M. ATP-binding cassette C transporters in human pancreatic carcinoma cell lines: upregulation in 5-fluorouracil-resistant cells. Pancreatology 2009, 9:136-144.
8. Lage H., Denkert C. Resistance to chemotherapy in ovarian carcinoma: recent results. Cancer Res. 2007, 176:51-60.
9. Materna V., Liedert B., Thomale J., Lage H. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int. J. Cancer 2005, 115:393-402.
10. Sebens Müerköster S., Werbing V., Sipos B., Debus M.A., Witt M., Grossmann M., Leisner D., Kappes H., Klöppel G., Altevogt P., Fölsch U.R., Schäfer H. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 2007, 26:2759-2768.
11. Geismann C., Morscheck M., Koch D., Ungefroren H., Arlt A., Tsao M.-S., Bachem M.G., Altevogt P., Fölsch U.R., Schäfer H., Sebens Müerköster S. Up-regulation of L1CAM in pancreatic duct cells is transforming Growth Factor b1- and Slug-dependent: role in malignant transformation of pancreatic cancer. Cancer Res. 2009, 69:4517-4526.
12. Stoeck A., Gast D., Sanderson M.P., Issa Y., Gutwein P., Altevogt P. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol. Oncol. 2007, 104:461-469.
13. Schachner M. Neural recognition molecules and synaptic plasticity. Curr. Opin. Cell Biol. 1997, 9:627-634.
14. Gast D., Riedle S., Schabath H., Schlich S., Schneider A., Issa Y., Stoeck A., Fogel M., Joumaa S., Wenger T., Herr I., Gutwein P., Altevogt P. L1 augments cell migration and tumor growth but not beta3 integrin expression in ovarian carcinomas. Int. J. Cancer 2005, 115:658-665.
15. Gavert N., Conacci-Sorrell M., Gast D., Schneider A., Altevogt P., Brabletz T., Ben-Ze'ev A. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J. Cell Biol. 2005, 168:633-642.
16. Izumoto S., Ohnishi T., Arita N., Hiraga S., Taki T., Hayakawa T. Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion. Cancer Res. 1996, 56:1440-1444.
17. Fogel M., Gutwein P., Mechtersheimer S., Riedle S., Stoeck A., Smirnov A., Edler L., Ben-Arie A., Huszar M., Altevogt P. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 2003, 362:869-875.
18. Rawnaq T., Quaas A., Zander H., Gros S.J., Reichelt U., Blessmann M., Wilzcak W., Schachner M., Sauter G., Izbicki J.R., Kaifi J.T. L1 is highly expressed in tumors of the nervous system: a study of over 8000 human tissues. J. Surg. Res. 2010, (Epub ahead of print).
19. Bergmann F., Wandschneider F., Sipos B., Moldenhauer G., Schniewind B., Welsch T., Schirrmacher P., Klöppel G., Altevogt P., Schäfer H., Sebens Müerköster S. Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma. Oncol. Rep. 2010, 24:909-915.
20. Chen M.M., Lee C.Y., Leland H.A., Silletti S. Modification of the L1-CAM carboy terminus in pancreatic adenocarcinoma cells. Tumour Biol. 2010, (Epub ahead of print).
21. Ben Q.-W., Wang J.-C., Liu J., Zhu Y., Yuan F., Yao W.-Y., Yuan Y.Z. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 2010, (Epub ahead of print).
22. Arlt M.J., Novak-Hofer I., Gast D., Gschwend V., Moldenhauer G., Grunberg J., Honer M., Schubiger P.A., Altevogt P., Krüger A. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res. 2006, 66:936-943.
23. Raveh S., Gavert N., Ben-Ze'ev A. L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett. 2009, 282:137-145.
24. Min J.-K., Kim J.-M., Li S., Lee J.W., Yoon H., Ryu C.J., Jeon S.H., Lee J.H., Kim J.Y., Yoon H.K., Lee Y.K., Kim B.H., Son Y.S., Choi H.S., Lim N.K., Kim D.G., Hong H.J. L1 cell adhesion molecule is a novel therapeutic target in intrahepatic cholangiocarcinoma. Clin. Cancer Res. 2010, 16:3571-3580.
25. Wolterink S., Moldenhauer G., Fogel M., Pfeifer M., Lüttgau S., Gouveia R., Costa J., Endell J., Moebius U., Altevogt P. Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Cancer Res. 2010, 70:2504-2515.
26. Bao S., Wu Q., Li Z., Sathornsumetee S., Wang H., McLendon R.E., Hjelmeland A.B., Rich J.N. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008, 68:6043-6048.
27. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351:337-345.
28. Knogler K., Grünberg J., Zimmermann K., Cohrs S., Honer M., Ametamey S., Altevogt P., Fogel M., Schubiger P.A., Novak-Hofer I. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Clin. Cancer Res. 2007, 13:603-611.
29. Oldham R.K., Dillman R.O. Monoclonal antibodies in cancer therapy: 25years of progress. J. Clin. Oncol. 2008, 26:1774-1777.
30. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 2005, 23:1147-1157.
31. Reichert J.M., Rosenzweig C.J., Faden L.B., Dewitz M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 2005, 23:1073-1078.
32. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
33. Smith I.E. Trastuzumab for early breast cancer. Lancet 2006, 367:107.
34. Mechtersheimer S., Gutwein P., Agmon-Levin N., Stoeck A., Oleszewski M., Riedle S., Postina R., Fahrenholz F., Fogel M., Lemmon V., Altevogt P. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J. Cell Biol. 2001, 155:661-673.
35. Gutwein P., Stoeck A., Riedle S., Gast D., Runz S., Condon T.P., Marmé A., Phong M.C., Linderkamp O., Skorokhod A., Altevogt P. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin. Cancer Res. 2005, 11:2492-24501.
36. Müerköster S., Arlt A., Witt M., Gehrz A., Haye S., March C., Grohmann F., Wegehenkel K., Kalthoff H., Fölsch U.R., Schäfer H. Usage of the NF-κB inhibitor Sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int. J. Cancer 2003, 104:469-476.
37. Teitz T., Wie T., Valentine M.B., Vanin E.F., Grenet J., Valentine V.A., Behm F.G., Look A.T., Lahti J.M., Kidd V.J. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 2000, 6:529-535.
38. Poulaki V., Mitsiades C.S., McMullan C., Fanourakis G., Negri J., Goudopoulou A., Halikias I.X., Voutsinas G., Tseleni-Balafouta S., Miller J.W., Mitsiades N. Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing. Invest. Ophthalmol. Vis. Sci. 2005, 46:358-366.
39. Harada K., Toyooka S., Shivapurkar N., Maitra A., Reddy J.L., Matta H., Miyajima K., Timmons C.F., Tomlinson G.E., Mastrangelo D., Hay R.J., Chaudhary P.M., Gazdar A.F. Deregulation of Caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 2002, 62:5897-5901.
40. Hopkins-Donaldson S., Ziegler A., Kurtz S., Bigosch C., Kandioler D., Ludwig C., Zangemeister-Wittke U., Stahel R. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA-methylation. Cell Death. Differ. 2003, 10:356-364.
41. Sebens Müerköster S., Werbing V., Koch D., Sipos B., Ammerpohl O., Kalthoff H., Tsao M.-S., Fölsch U.R., Schäfer H. Role of myofibroblasts on innate chemoresistance in pancreatic carcinoma - epigenetic down-regulation of caspases. Int. J. Cancer 2008, 123:1751-1760.
42. Kiefel H., Bondong S., Erbe-Hoffmann N., Hazin J., Riedle S., Wolf J., Pfeifer M., Arlt A., Schäfer H., Sebens Müerköster S., Altevogt P. L1CAM induces constitutive NF-κB activation in pancreatic adenocarcinoma cells by enhancing IL1β expression. Oncogene 2010, 29:4766-4778.
43. Harikumar K.B., Sung B., Tharakan S.T., Pandey M.K., Joy B., Guha S., Krishnan S., Aggarwal B.B. Sesamin manifests chemopreventive effects through the suppression of NF-kappaB-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol. Cancer Res. 2010, 8:751-761.
44. Sebens Müerköster S., Kötteritzsch J., Geismann C., Gast D., Kruse M.-L., Altevogt P., Fölsch U.R., Schäfer H. α5-Integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma. Int. J. Oncol. 2009, 34:243-253.
45. Kiefel H., Pfeifer M., Bondong S., Hazin J., Altevogt P. Linking L1CAM-mediated signalling to NF-κB activation. Trends Mol. Med. 2010, (Epub ahead of print).
46. Deng C., Lu Q., Zhang Z., Rao T., Attwood J., Yung R., Richardson B. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signalling. Arthritis Rheum. 2003, 48:746-756.
47. Loers G., Chen S., Grumet M., Schachner M. Signal transduction pathways implicated in neural recognition molecule L1 triggered neuroprotection and neuritogenesis. J. Neurochem. 2005, 92:1463-1476.
48. Novak-Hofer I., Cohrs S., Grünberg J., Friedli A., Schlatter M.C., Pfeifer M., Altevogt P., Schubiger P.A. Antibodies directed against L1-CAM synergize with Genistein in inhibiting growth and survival pathways in SKOV3ip human ovarian cells. Cancer Lett. 2008, 261:193-204.
49. Friedli A., Fischer E., Novak-Hofer I., Cohrs S., Ballmer-Hofer K., Schubiger P.A., Schibli R., Grünberg J. The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. Int. J. Biochem. Cell Biol. 2009, 41:1572-1580.